Antisense Therapeutics Limited logo

Antisense Therapeutics Limited

ASX:ANP.AX

Overview | Financials
Company Name Antisense Therapeutics Limited
Symbol ANP.AX
Currency AUD
Price 0.058
Market Cap 52,289,611
Dividend Yield 0%
52-week-range 0.05 - 0.11
Industry Drug Manufacturers—Specialty & Generic
Sector Healthcare
CEO Dr. James Garner B.Sc (Hons), B.Sc., M.A., M.A.I.C.D., M.B.A., MBA
Website https://www.antisense.com.au

An error occurred while fetching data.

About Antisense Therapeutics Limited

Antisense Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase II clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline

Related Stocks

Microba Life Sciences Limited logo

Microba Life Sciences Limited

MAP.AX

0.175 AUD

Noxopharm Limited logo

Noxopharm Limited

NOX.AX

0.067 AUD

Orthocell Limited logo

Orthocell Limited

OCC.AX

0.37 AUD

Emyria Limited logo

Emyria Limited

EMD.AX

0.046 AUD

MedAdvisor Limited logo

MedAdvisor Limited

MDR.AX

0.44 AUD

Biotron Limited logo

Biotron Limited

BIT.AX

0.05 AUD

Micro-X Limited logo

Micro-X Limited

MX1.AX

0.093 AUD

Invion Limited logo

Invion Limited

IVX.AX

0.005 AUD

Financials

Numbers are in millions USD

Numbers are in millions USD